Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 4/20 | 0.35 |
| ▸ | RAB9A | P51151 | 4/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL103608 | 0.85 | TSHR (0.39) | MAPTNPSR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL104166 | 0.85 | NPC1 (0.50) | PDE10AMAPTNPSR1NPC1RAB9A | |
| SCHEMBL102895 | 0.82 | PDE10A (0.47) | PDE10AMAPTNPSR1NPC1RAB9A | |
| SCHEMBL104046 | 0.79 | GRM5 (0.57) | PDE10AMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL103615 | 0.77 | GRM5 (0.40) | PDE10AMAPTNPSR1GRM5 | |
| SCHEMBL100895 | 0.77 | PDE10A (0.50) | PDE10AMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL103676 | 0.77 | ATP4A (0.48) | MAPTNPSR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1895446 | 0.75 | PDE10A (0.51) | PDE10AMAPTNPSR1NPC1RAB9A | |
| SCHEMBL2503225 | 0.75 | PDE10A (0.54) | PDE10AMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL15766922 | 0.72 | PDE10A (0.48) | PDE10AMAPTNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883826-B2 | Alkynyl derivatives as modulators of metabotropic glutamate receptors | ADDEX PHARMA SA (CH) | 2014-11-11 | — | — | US | disclosed |
| US-8674106-B2 | Alkynyl derivatives as modulators of metabotropic glutamate receptors | ADDEX PHARMA SA (CH) | 2014-03-18 | — | — | US | disclosed |
| US-20130178631-A1 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2013-07-11 | — | — | US | disclosed |
| US-20120277237-A1 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2012-11-01 | — | — | US | disclosed |
| EP-2426115-A2 | Alkynyl derivatives as modulators of metabotropic glutamate receptors | Addex Pharma SA (CH) | 2012-03-07 | — | — | EP | disclosed |
| US-8101637-B2 | Alkynyl derivatives as modulators of metatropic glutamate receptors | ADDEX PHARMA SA (CH) | 2012-01-24 | — | — | US | disclosed |
| US-20090124625-A1 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METATROPIC GLUTAMATE RECEPTORS | ADDEX PHARMACEUTICALS SA (CH) | 2009-05-14 | — | — | US | disclosed |
| EP-1765795-A2 | ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Addex Pharmaceuticals SA (CH) | 2007-03-28 | — | — | EP | disclosed |
| WO-2005123703-A2 | ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMACEUTICALS SA (CH) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178631-A1 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM5, GRM1, GRM2 | PDE10A 2028/4885MAPT 1113/4885NPSR1 123/4885 |
| US-20090124625-A1 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METATROPIC GLUTAMATE RECEPTORS | GRM5, GRM2, GRM1 | PDE10A 2311/4885MAPT 630/4885NPSR1 102/4885 |
| US-20120277237-A1 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM5, GRM1, GRM2 | PDE10A 2028/4885MAPT 1113/4885NPSR1 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.